IHC Antibodies with Tissue Microarray Validation / FFPE Validated Antibodies

IHC Antibodies for FFPE Tissue Analysis

Immunohistochemistry (IHC) antibodies are essential tools for visualizing protein expression within preserved tissue architecture, enabling detailed analysis of cellular localization, tissue organization, and disease-associated changes. Antibodies validated using Tissue Microarray (TMA) analysis provide an additional level of confidence by demonstrating consistent staining across a wide range of normal and cancer tissues under standardized conditions. Epithelial markers such as the EpCAM Antibody for IHC are commonly used to identify tumor cells in FFPE sections, while broader epithelial profiling can be explored through the cytokeratin antibody collection.

Tissue Microarray (TMA) Validation Across Normal and Cancer Tissues

Unlike single-tissue validation approaches, TMA-based immunohistochemistry enables direct comparison of staining patterns across dozens to hundreds of tissue types simultaneously. This approach supports evaluation of specificity, reproducibility, and biological relevance in formalin-fixed, paraffin-embedded samples. Antibodies validated in this way allow researchers to assess staining consistency across both normal and malignant tissues, improving confidence in target specificity and interpretation.

Reliable Detection of Epithelial, Immune, and Tumor Markers

Tissue microarray validation is particularly valuable in cancer research, where distinguishing tumor cells from surrounding stromal or immune components is critical. Immune profiling markers such as CD3 antibody help identify T lymphocyte populations, while proliferation markers including Ki-67 antibody highlight actively dividing cells within tumor regions. These markers complement epithelial targets and support comprehensive tissue characterization across diverse biological contexts.

Applications in Cancer Research and Biomarker Discovery

TMA-validated IHC antibodies support tumor profiling, biomarker discovery, and comparative pathology studies. By enabling simultaneous analysis of normal and malignant tissues, these antibodies help identify differential expression patterns relevant to disease progression and therapeutic targeting. Tumor-associated proteins such as p53 antibody are frequently used to assess oncogenic alterations, while combined marker panels improve accuracy in tissue classification and diagnostic research.

Consistent Performance in FFPE Immunohistochemistry

These antibodies are optimized for use in formalin-fixed, paraffin-embedded tissues and perform reliably under standard antigen retrieval conditions. Strong signal-to-background ratios and reproducible staining across tissue microarrays make them well suited for high-throughput tissue analysis and histological evaluation. Vascular-associated markers such as CD34 antibody further enable identification of endothelial structures and tumor-associated vasculature in complex tissue environments.

This TMA validated IHC antibody page is part of a broader IHC antibody panel offered by NSJ Bioreagents.

A selection of IHC antibody products is shown below to support a range of research applications.